Redhill Biopharma Ltd.(RDHL)

Description: RedHill Biopharma Ltd., a biopharmaceutical company, engages in the acquisition and development of patent-protected new formulations and combinations of existing drugs in advanced stages of development. The company's pipeline includes six clinical stage therapeutic candidates comprising RHB-101, a once daily controlled release patented formulation of Carvedilol for the treatment of hypertension, heart failure, and left ventricular dysfunction; RHB-102, a once daily controlled release oral formulation of Ondansetron for the prevention of nausea and vomiting for oncology-support treatments; and RHB-103, a proprietary oral fast dissolving thin film formulation of rizatriptan for the treatment of acute migraine headaches. Its pipeline also consists of RHB-104, a patented antibiotics drug for the treatment of inflammatory bowel disease focused on Crohn's disease patients; RHB-105, an antibiotics and proton pump inhibitor proprietary drug targeting helicobacter pylori infection; and RHB-106, a patented formulation in tablet form for the preparation and cleansing of the gastrointestinal tract. RedHill Biopharma Ltd. was founded in 2009 and is based in Tel Aviv, Israel.

---

Keywords: Medicine Biopharmaceutical Antibiotics Autoimmune Disease Hypertension Heart Failure Bacteria Gastrointestinal Inflammatory Bowel Disease Migraine Crohn's Disease Thin Film Dysfunction Gastroenterology Nausea Abdominal Pain Headache Gastrointestinal Tract Proton Treatment Of Hypertension Treatment Of Inflammatory Bowel Disease Helicobacter Migraine Headache Migraine Headaches Drug Targeting Rizatriptan Ventricular Dysfunction

---

Home Page: www.redhillbio.com

RDHL Technical Analysis

21 Ha’arba’a Street
Tel Aviv, 6473921
Israel
Phone: 972 3 541 3131

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)